BD GeneOhm™ MRSA ACP Assay
The BD GeneOhm™ MRSA ACP Assay is a qualitative in vitro diagnostic test for the direct detection of methicillin-resistant Staphylococcus aureus (MRSA) DNA from nasal swabs in patients at risk for nasal colonization. The BD GeneOhm MRSA ACP assay builds upon an already proven assay, the BD GeneOhm MRSA assay, by incorporating achromopeptidase (ACP) lysis, which results in fewer assay steps and less hands-on time. The simplified workflow allows for easier, more efficient laboratory detection of MRSA within 2 hours. Compared to culture methods requiring two to five days, this rapid turn-around time can be used to enhance any infection control program.
Prevention and Control of MRSA: The BD GeneOhm™ MRSA Assay
Extensive studies have demonstrated the advantages of a stringent infection control program including decreased hospital-acquired MRSA infections, length of stay, number of isolated patients, and significant savings from the decreased use of antibiotics.1,2 The availability of a definitive test result for MRSA within two hours of receiving the specimen enables decisions and actions one to three days earlier than standard culture-based methods.
The BD GeneOhm™ MRSA Assay detects a unique molecular sequence which confers a double specificity: half of this sequence comes from the S. aureus chromosome; the second half is within the genetic element carrying methicillin resistance, the SCCmec cassette.
The speed and flexibility of the BD GeneOhm MRSA ACP Assay provides a powerful new identification tool, which can help reduce the risk of further transmission and infection, helping to reduce healthcare costs.
Remarkable annual cost savings have been demonstrated in hospitals implementing active MRSA surveillance programs. With surveillance, hospitals were able to better identify and control the reservoir of MRSA which resulted in significantly reduced rates of infection.
Jernigan et. al. assessed the cost and benefit at a university hospital where active surveillance cultures were performed for high-risk patients.4 The study estimated that an active surveillance culture program could save between $20,062 and $462,067 annually while preventing 8 to 41 MRSA infections.2 In another study, Chaix et. al. concluded that targeted screening (identification) and isolation (prevention) are the most cost-effective strategies over a range of MRSA carriage rates on admission, efficacy of the control program and infection rates following transmission.5
By offering the capability of delivering definitive MRSA results in less than two hours, the BD GeneOhm™ MRSA Assay from BD has the potential to dramatically improve the cost-effectiveness of an infection control program.